Studies patient satisfaction and nerve blood markers with subcutaneous ocrelizumab in multiple sclerosis
Observes people with multiple sclerosis receiving ocrelizumab under the skin, measuring satisfaction.
Plain-language title generated from the registry record
Registry title: A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)
Key facts
- Where
- Bern and Zurich, SwitzerlandSee the 2 sites
Where in Switzerland
- Inselspital - Universitaetsspital BernBern, SwitzerlandTaking people
- Bellevue Medical Grop AGZurich, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hoffmann-La Roche
- Trial code
- NCT06780150
- Record updated
- 9 November 2026
- Original description
The main purpose of the study is to evaluate participant satisfaction after administration of ocrelizumab subcutaneously (SC) after 12 months using the therapy administration satisfaction questionnaire subcutaneous (TASQ-SC).Read full original descriptionShow less
SurfSubQ - A Prospective Longitudinal Multicenter Observational Study to Investigate Neurofilament Light Chain Levels and Patient Satisfaction After Subcutaneous Ocrelizumab Administration in Persons With Multiple Sclerosis
The main purpose of the study is to evaluate participant satisfaction after administration of ocrelizumab subcutaneously (SC) after 12 months using the therapy administration satisfaction questionnaire subcutaneous (TASQ-SC).
Inclusion: Diagnosis of MS; RMS and PPMS participants diagnosed according to the McDonald criteria of 2017 or revised McDonald criteria 2024; First treatment during the course of MS therapy with ocrelizumab SC according to the local prescribing information, regardless of the reason for starting treatment with ocrelizumab.
Exclusion: Prior or simultaneous participation in CONFIDENCE or MoOzaRt (ISRCTN55332718) non interventional study (NIS) at the same study site; Prior treatment with rituximab (MabThera®) or ublituximab (Briumvi®); Severe psychiatric disability; Participation in interventional studies investigating DMTs for MS; Pregnant women.